Paul Hudson, Sanofi CEO (Jeremy Paoloni/Abaca/Sipa USA(Sipa via AP Images))
May 21, 2024 09:58 AM EDTUpdated May 24, 01:57 PM
Deals
R&D
AI

Sanofi, Ope­nAI, For­ma­tion Bio an­nounce AI drug de­vel­op­ment part­ner­ship

Andrew Dunn

Senior Biopharma Correspondent

French phar­ma­ceu­ti­cal gi­ant Sanofi will work with the tech pow­er­house Ope­nAI and New York-based start­up For­ma­tion Bio to de­vel­op AI-pow­ered soft­ware in drug R&D, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times